Taken from the March/April 2018 issue of The Women’s Health Activist Newsletter. In 2015, Valeant, a pharmaceutical giant known for price gouging and shady business practices paid $1 billion in cash for a flawed sexual enhancement drug marketed to women...

Part of testosterone's role in a woman’s body is to contribute to libido and arousal, which is why many women will consider taking it if they experience an unwanted drop in sexual desire.

Popular culture tells us that many women lose interest in sex during or after menopausal transition, but those ageist and sexist messages aren’t supported by good scientific research. We want you to have the facts and offer a few helpful...

FOR IMMEDIATE RELEASE Contact: Shaniqua Seth at sseth@nwhn.org or 202.682-2640, ext. 225

Click image to download PDF of the report card. Report Card References 1 – Addyi’s FDA Warning Addyi’s life-threatening side effects were so grave that they warranted the strictest possible warning by the FDA—a “black box warning.” Those side effects...

Rather than a failed “fix-all” pill, NWHN encourages rigorous research be conducted exploring the causes of women’s sexual problems, possible solutions, and what, if anything, might constitute “normal” when it comes to women’s sexuality.

FOR IMMEDIATE RELEASE Contact: Nora Brodnitz at nora@wcsemail.com or 202-471-0043

FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson contact: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994

The NWHN is warning all women about the health risks of the new "pink pill" – known as flibanserin and branded as Addyi – alleged to boost female libido.

FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson and Susan Wood, contact Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994